http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0506994-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05a203d85ee01909eaf728dc16f0f6cb
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14
filingDate 2005-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18a85dd5749d2a7c706564ebac07555a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63be20ec3ba8a6f7926ce61650c50b06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f65fb8fc532df3653e909eb01710b1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2d2218150edce63080b13caab26b378
publicationDate 2007-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber BR-PI0506994-A
titleOfInvention triazole derivatives that inhibit vasopressin antagonist activity
abstract "Triazole Derivatives That Inhibit VASOPRESSIN ANTAGONIST ACTIVITY" Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein Het represents 2-pyrimidinyl or 2-pyridinyl; R1 represents H, C1-3 alkyl, or a nitrogen-containing heterocyclic ring; R 2 represents H, C 1-1 alkyl-benzyl and R 3 represents H, methyl, methoxy or chlorine; anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis) , mittlesmerchz, preeclampsia, premature ejaculation, premature labor (preterm) and Raynaud's syndrome.
priorityDate 2004-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393636
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559516
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419579030
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458395052
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID222
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393787
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID313

Total number of triples: 36.